Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Capicua transcriptional repressor pseudogene 25 (CICP25) is a processed or unprocessed pseudogene homologous to the capicua transcriptional repressor gene (CIC). It is annotated in human genome databases, such as GeneCards, as a non-functional gene segment without protein-coding capability[1]. While CIC is a functional transcriptional repressor involved in important cellular processes and disease states—particularly in the central nervous system and cancer progression—the CICP25 pseudogene does not encode a functional protein. Pseudogenes, including CICP25, may have roles in gene regulation at the DNA or RNA level (such as acting as decoys for regulatory RNA molecules), but there is no mechanism of action, drug targeting, or established biomarker application specific to CICP25[1][3][2][4]. CICP25 should not be confused with CIC, the functional capicua transcriptional repressor protein, which is a recognized transcription factor with documented biological and disease roles[2][4]. The pseudogene status makes CICP25 unsuitable for therapeutic targeting, drug development, or classic molecular classification beyond its nature as a pseudogene[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Capicua transcriptional repressor pseudogene 25 (CICP25).